** Drugmaker Ionis Pharmaceuticals' IONS.O shares rise 4.5% to $33.40 premarket
** IONS posts Q4 sales of $227 mln, above analysts' est of $137.6 mln - LSEG
** Co reports Q4 loss of 66 cents/share vs analysts' est loss of $1.12/share - LSEG
** Co expects 2025 rev to be over $600 mln; analysts on avg expect 2025 rev to be $676 mln - LSEG
** As of December 31, 2024, IONS had cash, cash equivalents and short-term investments of $2.3 bln
** Co forecasts cash, cash equivalents and short-term investments of about $1.7 bln for 2025
** IONS fell ~34% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。